AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
AcelRx Pharmaceuticals Inc
Operating Income
AcelRx Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
|
Operating Income
-$20m
|
CAGR 3-Years
25%
|
CAGR 5-Years
9%
|
CAGR 10-Years
5%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is AcelRx Pharmaceuticals Inc's Operating Income?
Operating Income
-20m
USD
Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Operating Income amounts to -20m USD.
What is AcelRx Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
5%
Over the last year, the Operating Income growth was 12%. The average annual Operating Income growth rates for AcelRx Pharmaceuticals Inc have been 25% over the past three years , 9% over the past five years , and 5% over the past ten years .